CINXE.COM

<!DOCTYPE html><html lang="en"><head><link rel="stylesheet" data-href="https://fonts.googleapis.com/css?family=Roboto+Slab%7COpen+Sans%7CRoboto&display=swap" data-optimized-fonts="true"/><title>FDA approves GSK’s Ojjaara for the treatment of patients with myelofibrosis and anaemia</title><link rel="icon" href="https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png"/><link rel="shortcut icon" type="image/x-icon" href="https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png?optimizer=image&format=webp&width=180&aspectRatio=1"/><link rel="apple-touch-icon" sizes="180x180" href="https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png?optimizer=image&format=webp&width=180&aspectRatio=1"/><link rel="canonical" href="/domains/magazine.pharmafile.com/articles/fda-approves-gsk-s-ojjaara-for-the-treatment-of-patients-with-my"/><meta name="application-name" content="FDA approves GSK’s Ojjaara for the treatment of patients with myelofibrosis and anaemia"/><meta name="apple-mobile-web-app-capable" content="yes"/><meta name="apple-mobile-web-app-status-bar-style" content="default"/><meta name="apple-mobile-web-app-title" content="FDA approves GSK’s Ojjaara for the treatment of patients with myelofibrosis and anaemia"/><meta name="format-detection" content="telephone=no"/><meta name="mobile-web-app-capable" content="yes"/><meta name="msapplication-TileColor" content="#1976D2"/><meta name="msapplication-tap-highlight" content="no"/><link rel="manifest" href="/manifest.json"/><meta name="twitter:url" content="https://magazine.pharmafile.com"/><meta name="theme-color" content="#1976D2"/><meta name="viewport" content="width=device-width, initial-scale=1"/><meta charSet="utf-8"/><meta itemProp="name" content="FDA approves GSK’s Ojjaara for the treatment of patients with myelofibrosis and anaemia"/><meta name="keywords" content="FDA approves GSK's Ojjaara for the"/><meta itemProp="description" content="Gsk has announced that the us food and drug administration (fda) has approved ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofib"/><meta name="description" content="Gsk has announced that the us food and drug administration (fda) has approved ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofib"/><meta itemProp="image" content="https://cdn.magloft.com/pdf-import/921/images/pages/pg-006.jpg"/><meta property="og:description" content="Gsk has announced that the us food and drug administration (fda) has approved ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofib"/><meta property="og:title" content="FDA approves GSK’s Ojjaara for the treatment of patients with myelofibrosis and anaemia"/><meta property="og:site_name" content="FDA approves GSK’s Ojjaara for the treatment of patients with myelofibrosis and anaemia"/><meta property="og:image" content="https://cdn.magloft.com/pdf-import/921/images/pages/pg-006.jpg"/><meta property="og:type" content="website"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="FDA approves GSK’s Ojjaara for the treatment of patients with myelofibrosis and anaemia"/><meta name="twitter:description" content="Gsk has announced that the us food and drug administration (fda) has approved ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofib"/><meta name="twitter:image" content="https://cdn.magloft.com/pdf-import/921/images/pages/pg-006.jpg"/><meta name="author" content="Pharmafile"/><meta property="article:author" content="Pharmafile"/><meta property="article:published_time" content="2023-10-01T00:00:00.000Z"/><meta name="twitter:site" content="@pharmafocus"/><meta name="twitter:creator" content="@pharmafocus"/><style>html{--heading-font: "Roboto Slab";--body-font: "Open Sans";--ui-font: "Roboto";--top-menu-title-font: "Roboto Slab";--top-menu-subtitle-font: "Roboto";--top-menu-items-font: "Roboto";--footer-menu-title-font: "Roboto Slab";--footer-menu-items-font: "Roboto";--background-color: #FFFFFF;--background-color-dark: #808080;--primary-color: #1976D2;--primary-color-dark: #0C3B69;--secondary-color: #795FF4;--secondary-color-dark: #250B9F;--accent-color: #D76FD6;--accent-color-dark: #80237F;--info-color: #41638C;--info-color-dark: #213246;--warning-color: #EF9338;--warning-color-dark: #89490B;--success-color: #20AD27;--success-color-dark: #105714;--danger-color: #DF4241;--danger-color-dark: #7B1515;--top-menu-background-color: #FFFFFF;--top-menu-background-color-dark: #808080;--footer-menu-background-color: #000000;--footer-menu-background-color-dark: #000000;--top-menu-heading-title-color: #000000;--top-menu-heading-title-color-dark: #000000;--top-menu-item-text-color: #000000;--top-menu-item-text-color-dark: #000000;--top-menu-item-icon-color: #000000;--top-menu-item-icon-color-dark: #000000;--navbar-height: 64px; }</style><link rel="stylesheet" data-href="https://use.typekit.net/nat8xfl.css" data-optimized-fonts="true"/><script type="text/javascript" src="https://cdn.jsdelivr.net/npm/cookie-bar/cookiebar-latest.min.js?customize=1&always=1&showNoConsent=1"></script><meta name="google-site-verification" content="1Gr9skOzVfL3FXDYTam8oONdREeoeMCoQWnlojFJHX0"/><style> #billboard-banner { text-align:center;} #billboard-banner img {width:100%; max-width:970px; height:auto; position:relative; top:70px;} </style><meta name="next-head-count" content="43"/><link rel="preconnect" href="https://fonts.googleapis.com"/><link rel="preconnect" href="https://fonts.gstatic.com"/><link rel="preload" href="/_next/static/css/229efe2956472d85.css" as="style"/><link rel="stylesheet" href="/_next/static/css/229efe2956472d85.css" data-n-g=""/><link rel="preload" href="/_next/static/css/7c74bf24f71f6c9d.css" as="style"/><link rel="stylesheet" href="/_next/static/css/7c74bf24f71f6c9d.css" data-n-p=""/><link rel="preload" href="/_next/static/css/eaa0062c2481f7ca.css" as="style"/><link rel="stylesheet" href="/_next/static/css/eaa0062c2481f7ca.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script defer="" src="https://fonts.googleapis.com/css?family=Open+Sans&display=swap" data-nscript="beforeInteractive"></script><script src="/_next/static/chunks/webpack-b653c683a51d8b57.js" defer=""></script><script src="/_next/static/chunks/framework-73b8966a3c579ab0.js" defer=""></script><script src="/_next/static/chunks/main-34cb81d5753e1fc4.js" defer=""></script><script src="/_next/static/chunks/pages/_app-9cc101b503fd5646.js" defer=""></script><script src="/_next/static/chunks/ad273671-3092333ffa02af02.js" defer=""></script><script src="/_next/static/chunks/876-c944523f292a2885.js" defer=""></script><script src="/_next/static/chunks/223-fe6833f316a5a95f.js" defer=""></script><script src="/_next/static/chunks/174-d95909d2aa5e8ec8.js" defer=""></script><script src="/_next/static/chunks/302-d0f1826200f9f2a4.js" defer=""></script><script src="/_next/static/chunks/pages/domains/%5Bdomain%5D/articles/%5Bslug%5D-12d0888066c7f18b.js" defer=""></script><script src="/_next/static/1bBCYhXOG7wsYuaBifvjK/_buildManifest.js" defer=""></script><script src="/_next/static/1bBCYhXOG7wsYuaBifvjK/_ssgManifest.js" defer=""></script><style data-styled="" data-styled-version="5.3.9"></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Slab%7COpen+Sans%7CRoboto&display=swap"/><link rel="stylesheet" href="https://use.typekit.net/nat8xfl.css"/></head><body><div id="__next"><div class="Layout_container__gktH6"><div class="Layout_navbar-container__gCfDZ" style="height:64px"><nav class="_wrapper_jbnbd_1"><div class="_container_jbnbd_15"><div class="_navbar-prefix_jbnbd_108"><div class="Layout_prefix__7W2Vq"><button><div class="_nav-arrow-left_1lm7t_183 _icon_1lm7t_1 icon"></div></button></div></div><a class="_navbar-brand_jbnbd_29" aria-label="Pharmafile" href="/"><div class="_navbar-image_jbnbd_40"><img alt="Logo" loading="lazy" decoding="async" data-nimg="fill" class="_image_jbnbd_43" style="position:absolute;height:100%;width:100%;left:0;top:0;right:0;bottom:0;color:transparent" sizes="100vw" srcSet="https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 54w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 70w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 82w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 96w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 110w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 128w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 138w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 192w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 200w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 252w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 260w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 298w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 378w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 384w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 520w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 640w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 756w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 828w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 1080w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 1200w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 1920w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 2048w" src="https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png"/></div><div class="_navbar-title_jbnbd_58 _navbar-title-hide_jbnbd_101"><span>Therapeutic areas in focus</span></div></a><div id="navbar-children-container" class="_navbar-children_jbnbd_116"><div class="_menu_1jhrl_1"><div class="_menu-wrapper_1jhrl_22"><div class="_menu-items_1jhrl_38"><a class="_menu-item_1jhrl_38" href="/"><div class="_menu-home_1lm7t_255 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Home</div><div class="_indicator_1jhrl_63"></div></a><a class="_menu-item_1jhrl_38 _active_1jhrl_70" href="/articles"><div class="_menu-articles_1lm7t_259 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Articles</div><div class="_indicator_1jhrl_63 _active_1jhrl_70"></div></a><a class="_menu-item_1jhrl_38" href="/collections"><div class="_menu-issues_1lm7t_263 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Issues</div><div class="_indicator_1jhrl_63"></div></a><a class="_menu-item_1jhrl_38" href="/account/login"><div class="_menu-account_1lm7t_411 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Log in</div><div class="_indicator_1jhrl_63"></div></a></div></div></div></div><div id="navbar-suffix" class="_navbar-suffix_jbnbd_108"><div class="Layout_menu-actions__vsDbI"><div class="Layout_install-button__FBfSr"><div class="Tooltip_tooltip__98Sw9"></div><button class="_button_19h3g_1 _text_19h3g_12 _medium_19h3g_38 _secondary_19h3g_22" type="button" style="color:var(--top-menu-item-icon-color, var(--background-color))" role="button" aria-label="Search" aria-labelledby="labeldiv" title="Search"><div class="_action-search_1lm7t_15 _icon-button_19h3g_19 _icon_1lm7t_1 icon" style="background-color:var(--top-menu-item-icon-color, var(--background-color))"></div></button></div></div></div></div></nav></div><div class="Layout_main__evUHx"><div class="Layout_spacer__qTBD3" style="height:64px"></div><div class=""><div class=""></div><div class=""><div id="print-article" class="_slug__article__BPEHu"><div class="Article-module_article__kO4b9"><div id="outer" data-widget="page-widget" style="background-color:#FFFFFF;padding:16px 0px 24px 0px;color:#000000;text-align:left;font-family:"Open Sans"" class="Widget-module_outer__PBh8P Page-module_outer__g0XXH"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>NEWS</p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h2><span style="font-family:"Roboto Slab"" class="__bold">FDA approves GSK’s Ojjaara for the treatment of patients with myelofibrosis and anaemia</span></h2></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold">GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis in adults with anaemia. </span></p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Ojjaara is a once-daily oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor and is currently the only approved medicine for both newly diagnosed and previously treated myelofibrosis patients with anaemia that treats the key manifestations of the disease, including anaemia, constitutional symptoms and splenomegaly (enlarged spleen).</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>The FDA’s approval of the drug follows data from the MOMENTUM trial and a sub-population of patients with anaemia in the SIMPLIFY-1 phase 3 trial. The MOMENTUM trial assessed the drug’s safety and efficacy, meeting all of its primary and key secondary endpoints and demonstrating statistically significant response. The most common adverse reactions in both trials were thrombocytopaenia, haemorrhage, bacterial infection, fatigue, dizziness, diarrhoea and nausea.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Kapila Viges, CEO of Myeloproliferative Neoplasms (MPN) Research Foundation, added: “We are thrilled to see momelotinib reach the clinic, giving patients and their physicians another option to help manage myelofibrosis. Any new treatment that takes steps toward unlocking the mysteries of this complex and chronic blood cancer represents great progress for the field.”</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Ruben A Mesa MD FACP, president and executive director of Atrium Health Levine Cancer Center and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, US, stated: “With momelotinib we have the potential to establish a new standard of care for myelofibrosis patients with anaemia. Addressing key manifestations of myelofibrosis, including anaemia, constitutional symptoms and splenomegaly, makes a significant difference in the treatment regimen for these patients who have limited options to address these aspects of the disease.”</p></div></div></div></div></div><div class="_slug__share-button__ettip"><hr/></div></div></div><div id="ControlBar" class="_slug__control-bar__Jj4LE"><div class="WrapAutoHide-module_navigation__9sdQy WrapAutoHide-module_visible__UN7GD"><div class="ControlBar-module_toc-wrapper__AF5eD"><div class="ControlBar-module_toc__mKXnp"><div class="ControlBar-module_white-blur__TGapK"><div class="ControlBar-module_toc-slider__i9fv1"></div></div><div class="ControlBar-module_control-bar__9Zqak"><button class=""><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none"><path d="M13.8287 19C13.5367 19 13.2467 18.873 13.0487 18.627L8.22066 12.627C7.92266 12.256 7.92666 11.726 8.23166 11.36L13.2317 5.35998C13.5847 4.93598 14.2157 4.87898 14.6407 5.23198C15.0647 5.58498 15.1217 6.21598 14.7677 6.63998L10.2927 12.011L14.6077 17.373C14.9537 17.803 14.8857 18.433 14.4547 18.779C14.2707 18.928 14.0487 19 13.8287 19Z" fill="white"></path></svg></button><button class=""><svg xmlns="http://www.w3.org/2000/svg" width="18" height="14" viewBox="0 0 18 14" fill="none"><path d="M6.75 0H1.125C0.503719 0 0 0.503719 0 1.125V4.5C0 5.12128 0.503719 5.625 1.125 5.625C1.74628 5.625 2.25 5.12128 2.25 4.5V2.25H6.75C7.37128 2.25 7.875 1.74628 7.875 1.125C7.875 0.503719 7.37128 0 6.75 0Z" fill="white"></path><path d="M16.875 0H11.25C10.6287 0 10.125 0.503719 10.125 1.125C10.125 1.74628 10.6287 2.25 11.25 2.25H15.75V4.5C15.75 5.12128 16.2537 5.625 16.875 5.625C17.4963 5.625 18 5.12128 18 4.5V1.125C18 0.503719 17.4963 0 16.875 0Z" fill="white"></path><path d="M16.875 7.875C16.2537 7.875 15.75 8.37872 15.75 9V11.25H11.25C10.6287 11.25 10.125 11.7537 10.125 12.375C10.125 12.9963 10.6287 13.5 11.25 13.5H16.875C17.4963 13.5 18 12.9963 18 12.375V9C18 8.37872 17.4963 7.875 16.875 7.875Z" fill="white"></path><path d="M6.75 11.25H2.25V9C2.25 8.37872 1.74628 7.875 1.125 7.875C0.503719 7.875 0 8.37872 0 9V12.375C0 12.9963 0.503719 13.5 1.125 13.5H6.75C7.37128 13.5 7.875 12.9963 7.875 12.375C7.875 11.7537 7.37128 11.25 6.75 11.25Z" fill="white"></path></svg></button><button class="" disabled=""><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none"><g opacity="0.25"><path d="M9.9995 19C9.7735 19 9.5465 18.924 9.3595 18.768C8.9355 18.415 8.8785 17.784 9.2315 17.36L13.7075 11.989L9.3925 6.62701C9.0465 6.19701 9.1145 5.56701 9.5445 5.22101C9.9755 4.87501 10.6045 4.94301 10.9515 5.37301L15.7795 11.373C16.0775 11.744 16.0735 12.274 15.7685 12.64L10.7685 18.64C10.5705 18.877 10.2865 19 9.9995 19Z" fill="white"></path></g></svg></button></div></div></div></div></div><div class="_slug__wrapper__0ZIJf"></div><div></div></div></div><script> //create a new element const terms = document.createElement('div'); //set id terms.setAttribute("id","billboard-banner"); //add the new element to html var body = document.querySelector('body'); body.appendChild(terms); document.querySelector("#billboard-banner").innerHTML = "<ins data-revive-zoneid='1569' data-revive-id='9c421b7e485bf2edfee09708a4d06e2e'></ins>"; //insert new element before header //document.body.insertAdjacentElement('afterbegin', terms); const insElement = document.querySelector("#__next"); insElement.before(terms); </script> <script async="" src="//ads.datateam.co.uk/www/delivery/asyncjs.php"></script><div class="_footer_j8nu5_1"><div class="_container_j8nu5_12"><div class="_footer-row_j8nu5_23"><div class="_footer-column_j8nu5_36 _flex-2_j8nu5_117"><div class="_footer-brand_j8nu5_43"><div class=""><img alt="Logo" loading="lazy" width="40" height="40" decoding="async" data-nimg="1" class="_footer-logo_j8nu5_57" style="color:transparent" srcSet="https://media.magloft.app/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png 1x, https://media.magloft.app/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png 2x" src="https://media.magloft.app/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png"/></div><div class="_content_j8nu5_67"><h3>Pharmafile</h3><p>Therapeutic areas in focus</p></div></div><div class="_footer-link-list_j8nu5_121"><div class="_block_j8nu5_129"><a class="_footer-link-item_j8nu5_92" rel="noreferrer" href="mailto:info@samedanltd.com"><div class="_form-email_1lm7t_143 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>info@samedanltd.com</span></a></div><div class="_block_j8nu5_129"><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://pwa.magloft.com/"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>www.samedanltd.com</span></a></div><a target="_blank" rel="noreferrer" class="_footer-link-item_j8nu5_92" href="http://www.samedanltd.com/page/13"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>Privacy Policy</span></a><a target="_blank" rel="noreferrer" class="_footer-link-item_j8nu5_92" href="http://www.samedanltd.com/page/13"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>Terms of Service</span></a></div></div><div class="_footer-column_j8nu5_36 _flex-1_j8nu5_39"><div class="_footer-brand_j8nu5_43"><div class="_status-accent_1lm7t_91 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><div class="_content_j8nu5_67"><h3>Categories</h3><p>Explore our inspiring content by topic</p></div></div><div class="_footer-link-list_j8nu5_121"><a class="_footer-link-item_j8nu5_92" href="/categories/infectious-diseases"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Infectious Diseases</a><a class="_footer-link-item_j8nu5_92" href="/categories/rare-diseases"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Rare Diseases</a><a class="_footer-link-item_j8nu5_92" href="/categories/dermatology"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Dermatology</a><a class="_footer-link-item_j8nu5_92" href="/categories/oncology"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Oncology</a><a class="_footer-link-item_j8nu5_92" href="/categories/respiratory"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Respiratory</a><a class="_footer-link-item_j8nu5_92" href="/categories/pain"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Pain</a><a class="_footer-link-item_j8nu5_92" href="/categories/neurology"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Neurology</a><a class="_footer-link-item_j8nu5_92" href="/categories/cardiovascular"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Cardiovascular</a><a class="_footer-link-item_j8nu5_92" href="/categories/womens-health"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Women's Health</a><a class="_footer-link-item_j8nu5_92" href="/categories/news"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>News</a></div></div><div class="_footer-column_j8nu5_36 _flex-1_j8nu5_39"><div class="_footer-brand_j8nu5_43"><div class="_share-action_1lm7t_463 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><div class="_content_j8nu5_67"><h3>Social Footprints</h3><p>Follow us on our Social Media Channels</p></div></div><div class="_footer-link-list_j8nu5_121"><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://twitter.com/pharmafocus"><div class="_share-twitter_1lm7t_487 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span class="_footer-text_j8nu5_125">X</span></a><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://www.linkedin.com/company/samedan-ltd/"><div class="_share-linkedin_1lm7t_483 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span class="_footer-text_j8nu5_125">linkedin</span></a></div></div></div></div></div></div><div class="Toastify"></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"domain":"magazine.pharmafile.com","pwa":{"id":663,"publicationId":14881,"pwaOptinId":655,"domain":"magazine.pharmafile.com","config":{"access":{"concurrentLimit":null,"restrictAnonymous":null,"disableSignup":null,"disableLogin":null,"disableLoginMessage":null,"disableSearchIndexing":false,"signupUrl":null,"resetPasswordUrl":null,"isUsernameLogin":null,"disableEditProfile":null,"formUrl":null,"customMarginResetPassword":null},"push":{"google":{"serverPublicKey":"BM0A-3PI9oRiVvVNuci8EbmGIC655KFzdqh9tQxnt5n6T-oECeS2hReTgrjYtIeeK0wsWfMB6VixaHT_RxZ15J0"}},"tracking":{"facebook":{"appId":null,"pixelId":null},"google":{"measurementId":"G-L1MVP1ECDJ"},"gtm":null,"sentry":true},"payment":{"stripe":null,"bypassPayment":null,"mode":"none","external":null,"currency":null},"email":{"readerOptin":false},"firebase":null,"customHtml":{"head":"\u003clink rel=\"stylesheet\" href=\"https://use.typekit.net/nat8xfl.css\"\u003e\n\u003cscript type=\"text/javascript\" src=\"https://cdn.jsdelivr.net/npm/cookie-bar/cookiebar-latest.min.js?customize=1\u0026always=1\u0026showNoConsent=1\" onload=\"setupCookieBar();\"\u003e\u003c/script\u003e\n\u003c!-- Google Search console Verification --\u003e\n\u003cmeta name=\"google-site-verification\" content=\"1Gr9skOzVfL3FXDYTam8oONdREeoeMCoQWnlojFJHX0\" /\u003e\n\u003cstyle\u003e\n#billboard-banner { text-align:center;}\n#billboard-banner img {width:100%; max-width:970px; height:auto; position:relative; top:70px;}\n\u003c/style\u003e","body":"\u003cscript\u003e\n //create a new element\n const terms = document.createElement('div');\n //set id\n terms.setAttribute(\"id\",\"billboard-banner\");\n //add the new element to html\n var body = document.querySelector('body');\n body.appendChild(terms);\n document.querySelector(\"#billboard-banner\").innerHTML = \"\u003cins data-revive-zoneid='1569' data-revive-id='9c421b7e485bf2edfee09708a4d06e2e'\u003e\u003c/ins\u003e\"; \n //insert new element before header\n//document.body.insertAdjacentElement('afterbegin', terms);\n const insElement = document.querySelector(\"#__next\");\n insElement.before(terms);\n\u003c/script\u003e\n\u003cscript async src=\"//ads.datateam.co.uk/www/delivery/asyncjs.php\"\u003e\u003c/script\u003e"},"account":{"emailEditable":true,"customSubscriptionText":null,"customSubscriptionURL":null,"enableSubscriptionTitle":null},"checkout":null},"design":{"colors":{"backgroundColor":"#FFFFFF","primaryColor":"#1976D2","secondaryColor":"#795FF4","accentColor":"#D76FD6","infoColor":"#41638C","warningColor":"#EF9338","successColor":"#20AD27","dangerColor":"#DF4241","topMenuBackgroundColor":"#FFFFFF","topMenuHeadingTitleColor":"#000000","topMenuHeadingIconColor":null,"topMenuItemTextColor":"#000000","topMenuItemIconColor":"#000000","footerMenuBackgroundColor":"#000000","footerMenuHeadingTitleColor":null,"footerMenuHeadingTextColor":null,"footerMenuHeadingIconColor":null,"footerMenuItemTextColor":null,"footerMenuItemIconColor":null},"images":{"icon":"https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png","feature":"https://cdn.magloft.com/defaults/feature-graphic.jpg","topMenuIcon":"https://cdn.magloft.com/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png","footerMenuIcon":"https://cdn.magloft.com/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png","alphaChannelIcon":null},"fonts":{"heading":"roboto-slab","body":"open-sans","ui":"roboto","topMenuTitle":"roboto-slab","topMenuItems":null,"topMenuSubtitle":null,"footerMenuTitle":"roboto-slab","footerMenuItems":null},"menuItems":{"collections":{"title":"Issues"},"articles":{"title":null},"account":{"title":null},"icons":{"enabled":true}},"footerShape":"flat","issueCoverAspectRatio":0.75,"fullscreenCollectionView":"auto","customOverlayToggleView":false,"defaultViewMode":"html","categories":"flat","purchaseList":true,"libraryList":false,"noteList":false,"textToSpeech":false},"layout":{"banners":[{"image":"https://cdn.magloft.com/pwa-663/pwa/banner/994f2837-a9d2-437b-92bc-e0b130e07bf6.png","title":"Pharmafile Magazine","isHidden":true,"action":{"type":"url","href":"https://www.pharmafile.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}],"bottomBanners":[{"image":"https://cdn.magloft.com/pwa-663/pwa/banner/f3f87ce8-ef8e-4547-b63f-f4805a25e350.png","title":"Samedan","isHidden":false,"action":{"type":"url","href":"http://www.samedanltd.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}],"columnSeparator":"shadow","tabs":[{"route":"","title":"Home","icon":"menu-home","visible":true},{"route":"/articles","title":"Articles","icon":"menu-articles","visible":true},{"route":"/collections","title":"Collections","icon":"menu-issues","visible":true},{"route":"/account","title":"Account","icon":"menu-account","visible":true}],"topMenu":{"showLogo":true,"showSubtitle":true,"showTitle":false,"height":"64px"},"navbar":{"animation":false,"style":"logo-left"},"sections":[{"fullWidth":true,"backgroundColor":"transparent","columnSeparator":"none","columns":[{"size":5,"blocks":[{"type":"banner","image":"https://cdn.magloft.com/pwa-663/pwa/banner/994f2837-a9d2-437b-92bc-e0b130e07bf6.png","isHidden":true,"title":"Pharmafile Magazine","action":{"type":"url","href":"https://www.pharmafile.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}]}]},{"fullWidth":false,"backgroundColor":null,"columnSeparator":"shadow","columns":[{"size":8.5,"blocks":[{"type":"issue-slider","condition":null,"color":"#F50D0D","title":"Latest Issues","issueIds":[51652,50092,47546,47328],"thumbnail":{"style":"overlay","size":"tall"},"borderRadius":null,"zoomOnHover":true,"issues":null},{"type":"article-list","condition":null,"color":"#000000","title":"Trending","variant":"variant-b","articleIds":[258239,258236,258240,258242,258238,258237],"articles":null},{"type":"article-category","condition":null,"color":"#F50D0D","title":"Rare Diseases","variant":"variant-b","categoryId":42211,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/62a51415-ed19-4d78-8601-68087122c29b.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Infectious Diseases","variant":"variant-a","categoryId":42331,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/253ea686-a135-4a29-b1a2-f8a0b400a4f5.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Dermatology","variant":"variant-a","categoryId":42212,"backgroundColor":null,"image":null,"articles":null,"category":null},{"type":"article-list","condition":null,"color":"#195AA6","title":"Pain","variant":"variant-a","articleIds":[183367,183366,183365],"articles":null}]},{"size":3.5,"blocks":[{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Pharmafile Archive","description":"Browse older editions","action":{"type":"url","href":"https://en.calameo.com/subscriptions/6188509","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"ad","title":"Advertisement","advertisementIds":[1974],"adCampaignId":null,"condition":null},{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Sign up to our Newsletters","description":"Sign up to our newsletters and digital magazines","action":{"type":"url","href":"https://curwoodcmsltd.formstack.com/forms/samedan","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"guide-install","color":"#195AA6","title":"How to Install","condition":null},{"type":"ad","title":"Advertisement","advertisementIds":[2235],"adCampaignId":null,"condition":null}]}]},{"fullWidth":true,"backgroundColor":"transparent","columnSeparator":"none","columns":[{"size":5,"blocks":[{"type":"banner","image":"https://cdn.magloft.com/pwa-663/pwa/banner/f3f87ce8-ef8e-4547-b63f-f4805a25e350.png","isHidden":false,"title":"Samedan","action":{"type":"url","href":"http://www.samedanltd.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}]}]}],"columns":[{"size":8.5,"blocks":[{"type":"issue-slider","condition":null,"color":"#F50D0D","title":"Latest Issues","issueIds":[51652,50092,47546,47328],"thumbnail":{"style":"overlay","size":"tall"},"borderRadius":null,"zoomOnHover":true,"issues":null},{"type":"article-list","condition":null,"color":"#000000","title":"Trending","variant":"variant-b","articleIds":[258239,258236,258240,258242,258238,258237],"articles":null},{"type":"article-category","condition":null,"color":"#F50D0D","title":"Rare Diseases","variant":"variant-b","categoryId":42211,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/62a51415-ed19-4d78-8601-68087122c29b.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Infectious Diseases","variant":"variant-a","categoryId":42331,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/253ea686-a135-4a29-b1a2-f8a0b400a4f5.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Dermatology","variant":"variant-a","categoryId":42212,"backgroundColor":null,"image":null,"articles":null,"category":null},{"type":"article-list","condition":null,"color":"#195AA6","title":"Pain","variant":"variant-a","articleIds":[183367,183366,183365],"articles":null}]},{"size":3.5,"blocks":[{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Pharmafile Archive","description":"Browse older editions","action":{"type":"url","href":"https://en.calameo.com/subscriptions/6188509","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"ad","title":"Advertisement","advertisementIds":[1974],"adCampaignId":null,"condition":null},{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Sign up to our Newsletters","description":"Sign up to our newsletters and digital magazines","action":{"type":"url","href":"https://curwoodcmsltd.formstack.com/forms/samedan","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"guide-install","color":"#195AA6","title":"How to Install","condition":null},{"type":"ad","title":"Advertisement","advertisementIds":[2235],"adCampaignId":null,"condition":null}]}]},"seo":{"home":{"title":"Pharmafile - Therapeutic Areas in focus","description":"Pharma and healthcare legal \u0026 regulatory requirements, financial trends, research, tech, innovation, market insights, analysis, case studies and more","image":"https://cdn.magloft.com/pwa-663/seo/image/9a7a0d77-c45b-4ca4-8317-060aec365417.png","imageAlt":"Pharmafile magazine covers"},"articles":{"title":"Pharmafile Articles","description":"In depth articles covering AI Drug Discovery, Biomarkers, Drug Development, Clinical Trials, Personalised Medicine, Gene Editing, Biosimilars, Market Access, Real World Data, Wearables/ Interventional Devices and Patient Experience","image":"https://cdn.magloft.com/pwa-663/seo/image/a32f5169-eb7c-4073-9c9c-517e7c19e85d.png","imageAlt":"Pharmafile - Articles"},"issues":{"title":"Editions of Pharmafile","description":"Pharmafile includes in depth analysis of therapy areas including: Oncology, Pain Management, Respiratory Diseases, Rare Diseases, Cardiovascular \u0026 Metabolic, Neurological Disorders","image":"https://cdn.magloft.com/pwa-663/seo/image/48839896-f6a6-4404-8744-5e2ef6e70111.png","imageAlt":"Pharmafile - Issues"},"account":{"title":"Pharmafile - Account","description":"Manage your Pharmafile Reader Account...","image":"https://cdn.magloft.com/pwa-663/seo/image/898ff4a9-6db8-47f0-b26b-e2774d221dc2.png","imageAlt":"Reader Account"}},"strings":{"app":{"title":"Pharmafile","subtitle":"Therapeutic areas in focus"},"social":{"facebook":null,"twitter":"https://twitter.com/pharmafocus","linkedin":"https://www.linkedin.com/company/samedan-ltd/","youtube":null,"instagram":null},"topMenu":{"title":null,"subtitle":"Therapeutic areas in focus"},"footerMenu":{"title":"Pharmafile","subtitle":null,"description":null,"email":["info@samedanltd.com"],"privacyUrl":"http://www.samedanltd.com/page/13","termsUrl":"http://www.samedanltd.com/page/13","links":[{"name":"www.samedanltd.com","url":"https://pwa.magloft.com/"}]},"pages":null},"customFonts":[],"phrases":{},"trialEndAt":null,"bypassSubscription":false},"publication":{"id":14881,"title":"Pharmafile","properties":{"subtitle":null,"appIcon":"images/defaults/app-icon.png","promotionalText":null,"companyName":null,"emailReplyTo":"","privacyUrl":null,"termsUrl":null}},"categories":[{"id":42210,"slug":"infectious-diseases","title":"Infectious Diseases","color":"#444444","issueCount":0,"articleCount":4,"categoryGroupIds":[]},{"id":42211,"slug":"rare-diseases","title":"Rare Diseases","color":"#444444","issueCount":0,"articleCount":16,"categoryGroupIds":[]},{"id":42212,"slug":"dermatology","title":"Dermatology","color":"#444444","issueCount":0,"articleCount":6,"categoryGroupIds":[]},{"id":42331,"slug":"oncology","title":"Oncology","color":"#444444","issueCount":0,"articleCount":11,"categoryGroupIds":[]},{"id":42332,"slug":"respiratory","title":"Respiratory","color":"#444444","issueCount":0,"articleCount":4,"categoryGroupIds":[]},{"id":42333,"slug":"pain","title":"Pain","color":"#444444","issueCount":0,"articleCount":3,"categoryGroupIds":[]},{"id":42334,"slug":"neurology","title":"Neurology","color":"#444444","issueCount":0,"articleCount":6,"categoryGroupIds":[]},{"id":42335,"slug":"cardiovascular","title":"Cardiovascular","color":"#444444","issueCount":0,"articleCount":5,"categoryGroupIds":[]},{"id":48101,"slug":"womens-health","title":"Women's Health","color":"#444444","issueCount":0,"articleCount":4,"categoryGroupIds":[]},{"id":42404,"slug":"news","title":"News","color":"#444444","issueCount":0,"articleCount":31,"categoryGroupIds":[]}],"pwaSubscriptions":[],"categoryGroups":[],"slug":"fda-approves-gsk-s-ojjaara-for-the-treatment-of-patients-with-my","article":{"id":237739,"slug":"fda-approves-gsk-s-ojjaara-for-the-treatment-of-patients-with-my","issueId":50092,"categoryIds":[42404],"title":"FDA approves GSK’s Ojjaara for the treatment of patients with myelofibrosis and anaemia","description":"GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis in adults with anaemia.","image":"https://cdn.magloft.com/pdf-import/921/images/pages/pg-006.jpg","cover":"https://cdn.magloft.com/publication-14881/screenshots/articles/237739.jpg?ts=1696237530","date":1696201200000,"unlockType":"free","categories":[],"pdfPageId":"2ATMWtT8EP5D","visible":true,"showOnToc":true,"bookmark":false,"position":8,"publicationId":14881,"pwaOptinId":null,"seoDescription":"Gsk has announced that the us food and drug administration (fda) has approved ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofib","classificationIds":[],"pwaSubscriptionIds":[],"source":"typeloft2","trending":false,"html":"\u003cpage-widget padding=\"16 0 24 0\"\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eNEWS\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h2\"\u003e\u003cspan style=\"font-family: \u0026quot;Roboto Slab\u0026quot;;\" class=\"__bold\"\u003eFDA approves GSK’s Ojjaara for the treatment of patients with myelofibrosis and anaemia\u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\"\u003eGSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis in adults with anaemia. \u003c/span\u003e\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eOjjaara is a once-daily oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor and is currently the only approved medicine for both newly diagnosed and previously treated myelofibrosis patients with anaemia that treats the key manifestations of the disease, including anaemia, constitutional symptoms and splenomegaly (enlarged spleen).\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eThe FDA’s approval of the drug follows data from the MOMENTUM trial and a sub-population of patients with anaemia in the SIMPLIFY-1 phase 3 trial. The MOMENTUM trial assessed the drug’s safety and efficacy, meeting all of its primary and key secondary endpoints and demonstrating statistically significant response. The most common adverse reactions in both trials were thrombocytopaenia, haemorrhage, bacterial infection, fatigue, dizziness, diarrhoea and nausea.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eKapila Viges, CEO of Myeloproliferative Neoplasms (MPN) Research Foundation, added: “We are thrilled to see momelotinib reach the clinic, giving patients and their physicians another option to help manage myelofibrosis. Any new treatment that takes steps toward unlocking the mysteries of this complex and chronic blood cancer represents great progress for the field.”\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eRuben A Mesa MD FACP, president and executive director of Atrium Health Levine Cancer Center and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, US, stated: “With momelotinib we have the potential to establish a new standard of care for myelofibrosis patients with anaemia. Addressing key manifestations of myelofibrosis, including anaemia, constitutional symptoms and splenomegaly, makes a significant difference in the treatment regimen for these patients who have limited options to address these aspects of the disease.”\u003c/paragraph-widget\u003e\u003c/page-widget\u003e","keywordPhrase":"FDA approves GSK's Ojjaara for the","articleAssets":[{"url":"https://cdn.magloft.com/reader/fonts/roboto-slab.css","extension":"css","contentType":"text/css"},{"url":"https://cdn.magloft.com/reader/fonts/open-sans.css","extension":"css","contentType":"text/css"}]},"publicationId":14881},"__N_SSG":true},"page":"/domains/[domain]/articles/[slug]","query":{"domain":"magazine.pharmafile.com","slug":"fda-approves-gsk-s-ojjaara-for-the-treatment-of-patients-with-my"},"buildId":"1bBCYhXOG7wsYuaBifvjK","isFallback":false,"gsp":true,"scriptLoader":[]}</script></body></html>